Search
Influenza A virus A/Tasmania/503/2020 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB16726ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Influenza B virus B/Singapore/INFTT-16-0610/2016 antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB15507ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Polyethylene glycol 300
go.drugbank.com/drugs/DB11161ApprovedLow molecular weight glycols are observed to exhibit antibacterial properties as well. PEG 300 is found in eye drops as a lubricant to temporarily relieve redness, burning and irritation of the eyes. … Polyethylene glycols are widely used in biochemistry, structural biology, and medicine in addition to pharmaceutical and chemical industries.
Categories: Compounds used in a research, industrial, or household settingKetobemidone
go.drugbank.com/drugs/DB06738InvestigationalThe most commonly cited equalisation ratio for analgesic doses is 25 mg of ketobemidone hydrobromide to 60 mg of morphine hydrochloride or sulfate and circa 8 mg of ketobemidone by injection. … This makes it useful for some types of pain that don't respond well to other opioids.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeNandrolone decanoate
go.drugbank.com/drugs/DB08804ApprovedIllicitInvestigationaleffect compared to nandrolone and other esters. … [A233789,A233849,L32564,L9464] The process for creating esters of [nandrolone] was patented in Spain in 1959[L33244] and in 1960, it was described as having a long duration of action and strong anabolic
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesInterferon alfa-n1
go.drugbank.com/drugs/DB00011ApprovedWithdrawnInterferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated.
Interferon alfa-n3
go.drugbank.com/drugs/DB00018ApprovedPurified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or polymorphisms including 2a, 2b and 2c). 166 residues, some are glycosylated (MW range from 16 kD to 27 kD).
Ecallantide
go.drugbank.com/drugs/DB05311ApprovedEcallantide is marketed by FDA and EMA under the trade name Kalbitor for subcutaneous injection. … Ecallantide is a potent and selective human plasma kallikrein inhibitor that is indicated for the symptomatic treatment of hereditary angioedema.
Vayarin
go.drugbank.com/drugs/DB09328ApprovedVayarin is a novel therapy for ADHD that appears to be effective in several studies [L1501, L1502, L1503]. … Cost of the drug and patient aversion to the taste of Vayarin were significant reasons for therapy failure [L1502].
Pimavanserin
go.drugbank.com/drugs/DB05316ApprovedInvestigational[A232783] It was approved by the FDA in April 2016 for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis thanks to favorable results from a pivotal six-week, randomized … Therefore, pimavanserin can be used to treat psychotic symptoms without causing extrapyramidal or worsening motor symptoms.